SPINEWAY: 2026 Half-Year Results

Spineway, a specialist in implants for severe spinal pathologies, continues its growth. In the first half of 2026, revenue reached €5.7 million, up 3% compared to 2025. This improvement is due to positive sales momentum, despite normalized supply chains and stable operating costs.

The operating result was -€1.6 million, impacted by regulatory investments and the implementation of a new ERP system. The financial result was positive thanks to a favorable exchange rate effect, but the net result remained negative at -€1.5 million.

To support its international growth strategy, Spineway has issued bonds to finance its development, thereby strengthening its cash position. This initiative should allow the company to continue investing in product certification and international expansion.